Xenon Pharmaceuticals Inc
XENE31.450USD
+0.950+3.11%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.41BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Xenon Pharmaceuticals Inc Unternehmen
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Unternehmensinformationen
BörsenkürzelXENE
Name des UnternehmensXenon Pharmaceuticals Inc
IPO-datumOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Anzahl der mitarbeiter316
WertpapierartOrdinary Share
GeschäftsjahresendeOct 17
Addresse3650 Gilmore Way
StadtVANCOUVER
BörseNASDAQ Global Market Consolidated
LandCanada
PostleitzahlV5G 4W8
Telefon16044843300
Websitehttps://www.xenon-pharma.com/
BörsenkürzelXENE
IPO-datumOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Ms. Andrea Marie Difabio, J.D.
Ms. Andrea Marie Difabio, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Canada
7.50M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Aug 3
Aktualisiert: Sun, Aug 3
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
46.54%
Investment Advisor
30.34%
Hedge Fund
23.10%
Private Equity
1.66%
Venture Capital
1.05%
Sovereign Wealth Fund
0.83%
Research Firm
0.77%
Pension Fund
0.56%
Bank and Trust
0.27%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
416
84.68M
110.35%
+9.65K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
2023Q1
347
63.79M
101.12%
-4.16M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
6.16M
8.03%
+73.87K
+1.21%
Mar 31, 2025
Avoro Capital Advisors LLC
5.74M
7.48%
+75.00K
+1.32%
Mar 31, 2025
Driehaus Capital Management, LLC
4.58M
5.97%
+64.26K
+1.42%
Mar 31, 2025
Wellington Management Company, LLP
3.79M
4.94%
+11.59K
+0.31%
Mar 31, 2025
Janus Henderson Investors
3.33M
4.33%
+458.34K
+15.99%
Mar 31, 2025
Capital International Investors
3.09M
4.03%
+541.52K
+21.26%
Mar 31, 2025
Braidwell LP
2.71M
3.53%
-204.09K
-7.00%
Mar 31, 2025
Polar Capital LLP
2.62M
3.42%
-74.62K
-2.77%
Mar 31, 2025
Commodore Capital LP
2.33M
3.03%
-415.00K
-15.15%
Mar 31, 2025
Capital World Investors
2.22M
2.9%
-69.82K
-3.04%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Neuroscience and Healthcare ETF
4.34%
Tema Neuroscience and Mental Health ETF
1.82%
ALPS Medical Breakthroughs ETF
1.62%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Goldman Sachs Future Health Care Equity ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Harbor Health Care ETF
0.42%
BNY Mellon Innovators ETF
0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.34%
iShares Health Innovation Active ETF
0.34%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil4.34%
Tema Neuroscience and Mental Health ETF
Anteil1.82%
ALPS Medical Breakthroughs ETF
Anteil1.62%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.86%
Goldman Sachs Future Health Care Equity ETF
Anteil0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.52%
Harbor Health Care ETF
Anteil0.42%
BNY Mellon Innovators ETF
Anteil0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.34%
iShares Health Innovation Active ETF
Anteil0.34%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
